Added to YB: 2026-03-13
Pitch date: 2026-03-11
HROW [bullish]
Harrow, Inc.
-1.77%
current return
Author Info
No bio for this author
Company Info
Harrow, Inc., an eyecare pharmaceutical company, engages in the discovery, development, and commercialization of ophthalmic pharmaceutical products in the United States.
Market Cap
$1.3B
Pitch Price
$36.20
Price Target
185.00 (+401%)
Dividend
N/A
EV/EBITDA
30.23
P/E
-258.09
EV/Sales
5.58
Sector
Pharmaceuticals
Category
growth
I continue to think $HROW is one of the most undervalued / mispriced growth stocks in the entire market.
HROW: Down 33% despite mgmt guiding CY26 rev +32% YoY, EBITDA +45% YoY (conservative). Trades 15x NTM EV/EBITDA. New indication approval next mo; July data could 4x Izeeho mkt share; G-Melt launch 18-24mo (potential biggest product). Doubling sales teams. CEO targets $250M qtrly rev by Q4'27 (~$1B CY28). At 35-40% EBITDA margins, $350-400M EBITDA by '28 = 4x EV/EBITDA today. Potential 5-bagger in 3yrs.
Read full article (2 min)